Blueprint
MYMETICS CORPORATION
Route de la Corniche 4
1066 Epalinges,
Switzerland
January
3, 2020
Via Edgar Correspondence
Chris
Edwards
Office
of Life Sciences
Division
of Corporation Finance
Securities
and Exchange Commission
100 F
Street, N.E.
Washington,
DC 20549
Preliminary
Information Statement on Schedule 14C
Filed
December 27, 2019
File
No. 000-25132
Dear
Mr. Edwards:
We have
received your correspondence dated December 31, 2019. We have
addressed your comment by reproducing it and providing our response
immediately thereafter.
General
Please revise your disclosure to describe any current plans,
arrangements or understandings relating to the issuance of any of
the newly authorized shares that would be available as a result of
the proposed increase in authorized shares, including the terms of
any current financing plans. If you have no such plans,
arrangements or understandings, please revise your disclosure to so
state.
Response: We have revised our
Preliminary Information Statement on Schedule 14C in response to
this comment.
We are
filing on EDGAR for SEC access only a marked version of the
Schedule 14C to reflect the changes referenced above in response to
the SEC’s comment letter. If you have any further comments or
questions regarding our response, please contact our legal counsel,
Ernest M. Stern, Culhane Meadows PLLC at (301) 910-2030. If you
cannot reach him, please contact the undersigned at ronald.kempers@mymetics.com.
Sincerely,
/s/
Ronald Kempers
Ronald
Kempers
cc:
Ernest M. Stern, Esq. (w/encl.)
Encl.